Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
Recommended Citation
Puri S, Leighl NB, Ismaila N, Rous FA, Ahluwalia A, Alluri K, Azar IH, Campbell T, Durm G, Feldman J, Florez N, Freeman-Daily J, Furuya N, Gadgeel S, Halmos B, Horinouchi H, Kuruvilla S, Macvicar GR, Malhotra N, Marrone KA, Mishra DR, Mullane M, Naidoo J, Owen DH, Pellini B, Presley CJ, Qin A, Roof L, Schenk EL, Sequist L, Singh N, Singhi EK, Suga JM, Velazquez AI, Wang Y, Price PW, Reuss JE, and Bazhenova L. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. J Clin Oncol 2026;44(7):15.
Document Type
Article
Publication Date
3-1-2026
Publication Title
Journal of clinical oncology
Abstract
PURPOSE: To provide evidence-based recommendations for patients with stage IV non-small cell lung cancer with driver alterations.
METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date.
RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines.
PubMed ID
41632926
ePublication
ePub ahead of print
Volume
44
Issue
7
First Page
15
Last Page
15
